Repository logo
 

Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.

Published version
Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/384681

Repository DOI

Thumbnail Image

Files

Bibliographic metadata (109.98 KB)
Primary Published version (1.02 MB)

Type

Article

Change log

Authors

Akingbola, Adewunmi  ORCID logo  https://orcid.org/0000-0001-7245-0340
Adegbesan, Abiodun  ORCID logo  https://orcid.org/0000-0001-9478-5360
Adegoke, Kolade  ORCID logo  https://orcid.org/0009-0006-1509-0274
Idahor, Courage  ORCID logo  https://orcid.org/0000-0002-5938-4817

Abstract

This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.

Description

Acknowledgements: Not Applicable. No funding was gotten for this research project.

Keywords

3207 Medical Microbiology, 32 Biomedical and Clinical Sciences, Biodefense, Prevention, Coronaviruses, Emerging Infectious Diseases, Vaccine Related, Pneumonia & Influenza, Genetics, Immunization, Infectious Diseases, Influenza, 3.4 Vaccines, Infection

Journal Title

NPJ Vaccines

Conference Name

Journal ISSN

2059-0105
2059-0105

Volume Title

10

Publisher

Springer Science and Business Media LLC

Publisher DOI

https://doi.org/10.1038/s41541-025-01145-6

Rights and licensing

undefined
Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/

Collections

Jisc Publications Router